Aop Orphan Pharmaceuticals Ag

Pharmaessentia Corporation

Aop Orphan Pharmaceuticals Ac

Aop Orphan Pharmaceuticals Gmbh

Orpha Swiss Gmbh

Rudolf Stefan Widmann

Ko-Chung Lin

Georg Strieder

Andreas Bernkop-Schnuerch

A parenteral formulation of esmolol hydrochloride for use in the treatment of a patient suffering from tachycardia comprising a lyophilized powder consisting of pure esmolol hydrochloride, wherein said powder is reconstituted to obtain a ready-to-use i.v. solution of esmolol hydrochloride at a concentration of 20-100 mg/mL, and said i.v. solution is directly administered to the patient, and further a method of producing a ready-to-use i.v. solution of esmolol hydrochloride by reconstituting a lyophilized powder consisting of pure esmolol hydrochloride with a solvent, characterized in that said solvent is an i.v. solvent devoid of alcohol or a buffer excipient, in an amount necessary to obtain a ready-to-use i.v. solution at a concentration of 20-100 mg/mL, and the ready-to-use i.v. solution containing a parenteral formulation of 20-100 mg/mL pure esmolol hydrochloride in an infusion device or consisting of a parenteral formulation of 20-100 mg/mL pure esmolol hydrochloride, WFI and/or saline solution, devoid of any alcohol or buffer excipients.

Parenteral esmolol formulation

The present invention relates to a pharmaceutical composition in the form of a storage-stable solution for the parenteral administration of ultrashort-effective &#x3b2;-adrenoreceptor antagonists, comprising a) an ultrashort-effective &#x3b2;-adrenoreceptor antagonist and/or a pharmaceutically acceptable salt thereof, b) water, and c) a cyclodextrin and/or a functional cyclodextrin derivative. The composition according to the invention has high stability, even without the presence of additional adjuvants.

Pharmaceutical composition for the parenteral administration of ultrashort-effective &#x3b2;-adrenoreceptor antagonists

Pharmaceutical composition for the parenteral administration of ultrashort-effective beta-adrenoreceptor antagonists

The present invention relates to a novel pharmaceutical composition free of gastric coating comprising anagrelide hydrochloride in combination with a non-pH dependent polymer and a pharmaceutically acceptable water soluble acid and its use for the treatment of essential thrombocythemia.

Composition for treatment of essential thrombocythemia

This invention relates to use protein-polymer conjugates described in the specification to treat various diseases, including disease is idiopaic myelofibrsis, polycythaemia vera, and essential thromobocythaemia.

Growing community of inventors

Purkersdorf, Austria

Rudolf Stefan Widmann